Clinical Epidemiology
Volume 13, 2021 - Issue
Original Research
Long-Term Risk of Skin Cancer and Lymphoma in Users of Topical Tacrolimus and Pimecrolimus: Final Results from the Extension of the Cohort Study Protopic Joint European Longitudinal Lymphoma and Skin Cancer Evaluation (JOELLE)
Alejandro Arana1 Department of Epidemiology, RTI Health Solutions, Barcelona, 08028, SpainCorrespondence[email protected]
https://orcid.org/0000-0002-1593-3124View further author information
https://orcid.org/0000-0002-1593-3124View further author information, Anton Pottegård2 Clinical Pharmacology, Pharmacy and Environmental Medicine, Institute of Public Health, University of Southern Denmark, Odense C, 5000, Denmarkhttps://orcid.org/0000-0001-9314-5679View further author information
https://orcid.org/0000-0001-9314-5679View further author information, Josephina G Kuiper3 The PHARMO Institute, Utrecht, 3528 AE, the Netherlandshttps://orcid.org/0000-0002-4487-3546View further author information
https://orcid.org/0000-0002-4487-3546View further author information, , Johan Reutfors5 Centre for Pharmacoepidemiology, Karolinska Institutet, Solna, 171 76, Stockholm, Swedenhttps://orcid.org/0000-0003-1372-4262View further author information
https://orcid.org/0000-0003-1372-4262View further author information, Brian Calingaert6 Department of Epidemiology, RTI Health Solutions, Research Triangle Park, NC, 27709-2194, USAhttps://orcid.org/0000-0001-8177-6326View further author information
https://orcid.org/0000-0001-8177-6326View further author information, , Elizabeth Crellin4 Clinical Practice Research Datalink (CPRD), The Medicines and Healthcare Products Regulatory Agency, London, E14 4PU, UKhttps://orcid.org/0000-0001-8774-224XView further author information
https://orcid.org/0000-0001-8774-224XView further author information, Marcus Schmitt-Egenolf5 Centre for Pharmacoepidemiology, Karolinska Institutet, Solna, 171 76, Stockholm, Sweden;7 Department of Public Health and Clinical Medicine, Umeå University, Umeå, 901 87, Swedenhttps://orcid.org/0000-0002-3858-8474View further author information
https://orcid.org/0000-0002-3858-8474View further author information, James A Kaye8 Department of Epidemiology, RTI Health Solutions, Waltham, MA, 02451-1623, USAhttps://orcid.org/0000-0002-9357-4227View further author information
https://orcid.org/0000-0002-9357-4227View further author information, , , , Daniel Dedman4 Clinical Practice Research Datalink (CPRD), The Medicines and Healthcare Products Regulatory Agency, London, E14 4PU, UKhttps://orcid.org/0000-0002-3699-5391View further author information
https://orcid.org/0000-0002-3699-5391View further author information, Eline Houben3 The PHARMO Institute, Utrecht, 3528 AE, the Netherlandshttps://orcid.org/0000-0002-9173-3335View further author information
https://orcid.org/0000-0002-9173-3335View further author information, Lia Gutiérrez1 Department of Epidemiology, RTI Health Solutions, Barcelona, 08028, Spainhttps://orcid.org/0000-0001-6280-1119View further author information
https://orcid.org/0000-0001-6280-1119View further author information, Jesper Hallas2 Clinical Pharmacology, Pharmacy and Environmental Medicine, Institute of Public Health, University of Southern Denmark, Odense C, 5000, Denmarkhttps://orcid.org/0000-0002-8097-8708View further author information
https://orcid.org/0000-0002-8097-8708View further author information & Susana Perez-Gutthann1 Department of Epidemiology, RTI Health Solutions, Barcelona, 08028, Spainhttps://orcid.org/0000-0001-5798-3691View further author information
https://orcid.org/0000-0001-5798-3691View further author information show all